Disease/Infection News

RSS

Universal testing for HIV can do more harm than good

The idea of early detection and cure is appealing. But if the test is unreliable, and the treatment itself harmful, universal testing can do more harm than good.

3 Jun 2010

Novel anti-malarial drug developed from blood thinner by Australian scientists

Malaria caused by a parasite that is borne in female mosquitoes and that spreads in humans through mosquito bites is a major public health problem and it kills more than a million people world wide each year. With the rise of resistance of many of the strains of the malaria parasite to most of the anti-malarial drugs the problem is escalating at an alarming pace.

2 Jun 2010

3.5 million FC2 Female Condoms ordered for distribution at 2010 World Cup

The Female Health Company announced that it has fulfilled an order for 3.5 million FC2 Female Condoms to be distributed for HIV/AIDS prevention to attendees at the 2010 World Cup. The 2010 World Cup will take place in The Republic of South Africa from June 11, 2010 to July 11, 2010.

2 Jun 2010

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

According to the Canadian Flu Report released today, 40 per cent of parents are now more interested in vaccinating themselves and their children against seasonal flu following last year's H1N1 outbreak. Yet, significant barriers and misinformation are still preventing many from actually seeking proper flu protection for their families.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

Faith-based organizations can play important role in response to HIV/AIDS in Central America: RAND study

Faith-based organizations such as churches and religious relief and development groups can play an important role in the response to HIV and AIDS in Central America, according to a new RAND Corporation report.

2 Jun 2010

Texas A&M uses pGAP and IBM supercomputing technology to boost tuberculosis research

IBM today announced that Texas A&M University used IBM supercomputing technology to carry out potentially life-saving tuberculosis research at a rate more than four times faster than was previously possible.

2 Jun 2010

Molecules similar to blood-thinning drug heparin can stop malaria from infecting red blood cells: Scientists

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.

2 Jun 2010

CCL5 protein plays protective role against Mycobacterium tuberculosis: New research

Ohio scientists hope to counter the re-emerging threat of tuberculosis with help from proteins from our bodies. In a research report published in the June 2010 print issue of the Journal of Leukocyte Biology, scientists show how the protein CCL5 plays a protective role in helping the body ward off this contagious, airborne disease in the early stages of infection.

2 Jun 2010

Ford Foundation announces $25M grant to fight hidden impact of HIV/AIDS in the U.S.

The Ford Foundation today announced a $25 million effort to fight the disproportionate yet largely hidden impact of HIV/AIDS on marginalized communities in the United States.

2 Jun 2010

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by Alnylam scientists and collaborators from Mount Sinai School of Medicine. In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced small non-coding RNAs, called small viral RNAs (svRNAs), which play a critical role in the replication of influenza A virus.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

Azithromycin as effective as penicillin for early-stage syphilis: Study

In a clinical trial involving HIV-negative volunteers with early-stage syphilis, researchers have found that antibiotic pills (azithromycin) are as effective as penicillin injections in curing early-stage syphilis. The study was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

2 Jun 2010

Platelets play important role in cerebral malaria: Research

Scientists are making strides against cerebral malaria, a fatal form of malaria in children that can ravage the brain and is extremely difficult to treat. New research points to platelets - known for their role in blood clotting - as playing an important role in the disease, stimulating the immune system and turning on molecules that increase inflammation. The inflammation leads to the obstruction of blood vessels in the brain, causing brain damage similar to that seen with a stroke.

2 Jun 2010

Plans to continue flu vaccination ban – intensive investigations ongoing

In the first quarter of this year nearly 300 children across Australia fell ill with fevers, vomiting and convulsions following administration of the seasonal flu vaccine.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.

2 Jun 2010

AHF's Magic Johnson Testing America Tour arrives in Wilmington to offer free HIV testing

AHF's Magic Johnson 'Testing America' Tour, a six month, 48 state national cross country HIV testing tour, arrives in Wilmington, Delaware tomorrow and will offer free HIV testing, along with local partner AIDS Delaware from 10:00 AM to 2:00 PM in Rodney Square, 2 East 11th St. across from the DuPont Building.

31 May 2010

Amorfix provides update on development of blood test for vCJD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, provides an update on the development of a blood test for vCJD, one of its six product development programs.

31 May 2010

Disease/Infection News

Universal testing for HIV can do more harm than good

Novel anti-malarial drug developed from blood thinner by Australian scientists

3.5 million FC2 Female Condoms ordered for distribution at 2010 World Cup

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

Research findings advance the effort to develop AIDS vaccine

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

Faith-based organizations can play important role in response to HIV/AIDS in Central America: RAND study

Texas A&M uses pGAP and IBM supercomputing technology to boost tuberculosis research

Molecules similar to blood-thinning drug heparin can stop malaria from infecting red blood cells: Scientists

CCL5 protein plays protective role against Mycobacterium tuberculosis: New research

Ford Foundation announces $25M grant to fight hidden impact of HIV/AIDS in the U.S.

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

Azithromycin as effective as penicillin for early-stage syphilis: Study

Platelets play important role in cerebral malaria: Research

Plans to continue flu vaccination ban – intensive investigations ongoing

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

AHF's Magic Johnson Testing America Tour arrives in Wilmington to offer free HIV testing

Amorfix provides update on development of blood test for vCJD

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News